STOCK TITAN

Quince Therapeutics (QNCX) director granted stock options for 2,700 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Quince Therapeutics director David Lamond reported receiving a stock option grant covering 2,700 shares of common stock. The option has an exercise price of $0.947 per share and expires on June 11, 2036. All 2,700 shares underlying the option will vest in full on the one-year anniversary of the grant date. Following this award, Lamond holds options for 2,700 shares directly.

Positive

  • None.

Negative

  • None.
Insider Lamond David
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (Right to Buy) 2,700 $0.00 --
Holdings After Transaction: Director Stock Option (Right to Buy) — 2,700 shares (Direct)
Footnotes (1)
  1. [object Object]
Option shares granted 2,700 shares Director stock option award to David Lamond
Exercise price $0.947 per share Strike price of director stock option
Expiration date June 11, 2036 Option term end for Lamond’s grant
Underlying common shares 2,700 shares Common stock covered by the option
Total options after grant 2,700 shares Total derivative holdings reported following transaction
Director Stock Option (Right to Buy) financial
"security_title: "Director Stock Option (Right to Buy)""
stock option financial
"100% of the shares subject to this stock option will vest"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "0.9470""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this stock option will vest on the one-year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-11T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Quince Therapeutics (QNCX) director David Lamond report?

David Lamond reported receiving a stock option grant for 2,700 shares of Quince Therapeutics common stock. The award is a compensation-related option grant, not an open-market purchase or sale of existing shares.

What is the exercise price of David Lamond’s Quince Therapeutics stock options?

The granted options have an exercise price of $0.947 per share. This means Lamond can buy Quince Therapeutics common stock at $0.947 per share once the options vest and before they expire.

When do David Lamond’s Quince Therapeutics options vest?

One hundred percent of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Vesting must occur before Lamond can exercise the options to acquire the underlying common shares.

When do David Lamond’s Quince Therapeutics stock options expire?

The options expire on June 11, 2036. After that date, Lamond will no longer be able to exercise these options to purchase Quince Therapeutics common stock at the stated exercise price.

How many Quince Therapeutics shares are covered by David Lamond’s option after this grant?

After this grant, Lamond holds options covering 2,700 shares of Quince Therapeutics common stock. This reflects his total reported derivative holdings related to this award in the filing.

Was David Lamond’s Quince Therapeutics transaction an open-market buy or sell?

No, the filing describes a grant or award acquisition of stock options, coded as “A.” This is a compensation-related derivative award, not an open-market purchase or sale of Quince Therapeutics shares.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lamond David

(Last)(First)(Middle)
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD., SUITE 273

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (Right to Buy)$0.94706/11/2026A2,700 (1)06/11/2036Common Stock2,700$02,700D
Explanation of Responses:
1. 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.
/s/ Brendan Hannah as attorney-in-fact for David Lamond06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)